Articles
Phasing forward with Seqens
Three custom development and manufacturing organizations – PCAS S.A. in France, Chemie Uetikon in Germany and PCI Synthesis in the United States –…
Read moreNewsroom
API Manufacturing / General
API lifecycle management: A CDMO perspective
Didier Combis of Seqens CDMO explains why pharmaceutical companies should consider the specifics of the API when dealing with drug lifecycle management…
Read more
API Manufacturing / General
Developing Controlled Substances Requires a Whole New Level of Global Diligence
4 Best Practices For Taking the Right Precautions to Develop Safe and Effective controlled Substances By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO…
Read more
API Manufacturing / Articles / General
The Growth of the Generic Drug Marketplace
The Growth of the Generic Drug Marketplace: A Win-Win for Industry and Patients By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO Some…
Read more
API Manufacturing / Articles / General / Research and Development
Faster, Less Costly Cinacalcet Production is Among CDMO Responses to Alleviate Rising Cost of Drugs, Impact of Tariffs
Proprietary intermediates produced in Europe, U.S. rather than imported Across the world, the pressure to cut drug price costs has never been greater.
Read more
API Manufacturing
Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations
Working with Contract Development & Manufacturing Organizations (CDMOs) in Asia has become a popular strategy for European and U.S.-based sponsors because of the associated…
Read more
API Manufacturing / Articles / General
The CDMO’s Challenges Developing An Oral Suspension For Children
By, Didier Combis, Commercial Director, Seqens CDMO; Christine Adam, Business Development Manager, Unither Pharmaceuticals and Jean Francois Cordoliani, Site Director, Unither Développement Bordeaux…
Read more
General
Why sponsors are turning to Western sources for regulatory starting materials (RSMs)
By Don LaFerle, Senior Vice President, Custom Synthesis, Seqens CDMO The ICH Q7 defines RSMs (Regulatory Starting Materials) as the point at…
Read more
API Manufacturing / General
Potent project
The Villeneuve-la-Garenne plant continues its transformation through the Potent project, which will enable the group to access the production of active pharmaceutical ingredients…
Read more
API Manufacturing
Are CDMOs the Only Ones Reducing Drug Development Costs?
Recently the publication Life Science Leader interviewed the author of the book, “Drugs,…
Read more
API Manufacturing
Getting to the Bottom of Genotoxic Impurities in APIs
By Francis Finot, CEO, GeneEvolution and partner of SEQENS’LAB Addressing genotoxic impurities in the creation of Active Pharmaceutical Ingredients (APIs)…
Read more
API Manufacturing / General
When Does it Makes Sense for CDMOs to Collaborate?
If you think Indiana Jones, Harrison Ford’s character in the classic cliffhanger Raiders of the Lost Ark had a rough journey, you have…
Read more